Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: King, Madeline, Heil, Emily, Kuriakose, Safia, Bias, Tiffany, Huang, Vanthida, El-Beyrouty, Claudine, McCoy, Dorothy, Hiles, Jon, Richards, Lynette, Gardner, Julianne, Harrington, Nicole, Biason, Kenneth, Gallagher, Jason C.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2017
Teme:
Clinical Therapeutics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5487633/
https://ncbi.nlm.nih.gov/pubmed/28483952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00449-17
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items